000 02632cam  2200373za 4500
0019.830413
003CaOODSP
00520221107145526
007cr |||||||||||
008170403t20172015oncd    ob   f000 0 eng d
020 |a978-0-660-07209-8|z978-0-660-07210-4
040 |aCaOODSP|beng
043 |an-cn---
0861 |aHP40-174/2017E-PDF|zHP40-174/2017F-PDF
24500|aUpdate on the recommended use of hepatitis B vaccine |h[electronic resource].
2461 |iAt head of title: |aAdvisory committee statement (ACS), National Advisory Committee on Immunization (NACI)
260 |a[Ottawa] : |bPublic Health Agency of Canada, |c2017, c2015.
300 |a54 p. : |bcol. chart
500 |aTitle from cover.
500 |aIssued also in HTML format.
500 |a"Publication date: February 2017”--Verso of cover.
500 |aIssued also in French under title: Mise à jour des recommandations concernant l’utilisation du vaccin contre l’hépatite B.
500 |aThe catalogue number (HP40-174/2017F-PDF) and ISBN (978-0-660-07210-4) for the French edition have been copied in this publication.
504 |aIncludes bibliographical references.
520 |a"This statement will supplement previous NACI statements on hepatitis B (HB) by: providing an overview of current HB epidemiology in Canada and national sources of HB-related surveillance; reviewing evidence pertaining to primary and booster immunization in those vaccinated as infants and in individuals with diabetes and immunocompromising conditions; reviewing evidence pertaining to indications for HB immunoglobulin (HBIg) administration; and making recommendations regarding existing HB immunization schedules, serological testing of immunocompromised persons, and surveillance and research priorities. The primary goal of the statement is to provide further guidance on the need for re-immunization of adolescents who have received routine immunization with a HB containing vaccine in infancy"--Introd., p. 4.
69207|2gccst|aHepatitis
69207|2gccst|aImmunization
69207|2gccst|aAdolescents
7101 |aCanada. |bNational Advisory Committee on Immunization.
7102 |aPublic Health Agency of Canada.
77508|tMise à jour des recommandations concernant l’utilisation du vaccin contre l’hépatite B |w(CaOODSP)9.830414
85640|qPDF|s1.75 MB|uhttps://publications.gc.ca/collections/collection_2017/aspc-phac/HP40-174-2017-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-use-hepatitis-b-vaccine.html